Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Solid cancers

Solid cancers

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Solid cancers

4 trials tracked for Solid cancers.

4Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 1 Phase 1 3
  1. Phase 2 A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study Completed
  2. Phase 1 A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer Completed
  3. Phase 1 A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists Completed
  4. Phase 1 A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
High NLRP-3 Expression Linked to Poor Survival in Solid Cancers
Oncology Meta-analysis
High NLRP-3 Expression Linked to Poor Survival in Solid Cancers High NLRP-3 levels linked to worse outcomes in solid cancers
Meta-analysis shows high NLRP-3 expression predicts worse overall and disease-free survival in solid tumors, with HR 2.12 for OS.
Higher levels of the NLRP-3 protein are linked to shorter survival times and more advanced disease in several types of solid tumors.
Aug 22, 2026